Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03463275 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single dose | EXPERIMENTAL | - |
| Multiple dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-03463275 | DRUG | Oral single 20 mg dose as two 10mg controlled release tablets |
| Placebo | DRUG | Oral single dose as matching placebo |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, and a total body weight \>50 kg (110 lbs). * Japanese subjects must have four Japanese grandparents who were born in Japan. Exclusion Criteria: * Subjects that are genot...
PF-03463275 is an investigational small molecule drug developed by Pfizer, Inc. (NYSE: PFE). It is a selective inhibitor of the glycine transporter 1 (GlyT1) protein, encoded by the SLC6A9 gene. The drug has been studied in a Phase 1 clinical trial in healthy male volunteers.
PF-03463275 targets SLC6A9, which encodes the glycine transporter 1 (GlyT1) protein. It acts as an inhibitor of this transporter. By inhibiting GlyT1, the drug is designed to modulate glycine levels in the brain, a mechanism being explored for potential central nervous system applications.
PF-03463275 is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is responsible for the research and clinical development of this investigational compound.
PF-03463275 is in Phase 1 clinical development. It has not been approved by the FDA or any regulatory agency. The only reported trial was a Phase 1 study that has been completed, and no active trials are currently listed.
PF-03463275 has been evaluated in one completed Phase 1 clinical trial, NCT01159626, titled "Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects." The trial enrolled 40 healthy male volunteers in the United States and was randomized, double-blind, and controlled.